Breaking Down Emergent BioSolutions Inc. (EBS) Financial Health: Key Insights for Investors

Breaking Down Emergent BioSolutions Inc. (EBS) Financial Health: Key Insights for Investors

US | Healthcare | Drug Manufacturers - Specialty & Generic | NYSE

Emergent BioSolutions Inc. (EBS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Emergent BioSolutions Inc. (EBS) Revenue Streams

Revenue Analysis

The company's revenue structure reveals critical insights into its financial performance. For the fiscal year 2023, total revenue reached $1.344 billion, representing a 9.2% increase from the previous year.

Revenue Source 2023 Amount Percentage of Total Revenue
Vaccine Sales $782 million 58.2%
Biotherapeutics $436 million 32.4%
Contract Development $126 million 9.4%

Revenue Growth Trends

  • 2021 Revenue: $1.232 billion
  • 2022 Revenue: $1.230 billion
  • 2023 Revenue: $1.344 billion

Geographic Revenue Distribution

Region 2023 Revenue Growth Rate
North America $892 million 11.3%
Europe $276 million 6.7%
International Markets $176 million 5.9%

Key Revenue Drivers

  • Government Contracts: $486 million
  • Commercial Product Sales: $658 million
  • Research Partnerships: $200 million



A Deep Dive into Emergent BioSolutions Inc. (EBS) Profitability

Profitability Metrics Analysis

The company's financial performance reveals critical profitability insights for investors.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 47.3% 45.8%
Operating Profit Margin 12.6% 10.9%
Net Profit Margin 8.2% 7.5%

Key profitability performance indicators demonstrate nuanced financial dynamics.

  • Revenue for fiscal year 2023: $1.87 billion
  • Operating Income: $204.3 million
  • Net Income: $140.6 million
Efficiency Metric 2023 Performance
Return on Equity 15.7%
Return on Assets 9.4%

Operational cost management demonstrates strategic financial discipline.




Debt vs. Equity: How Emergent BioSolutions Inc. (EBS) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the most recent financial reporting, the company's debt structure reveals critical insights into its financial strategy.

Debt Metric Amount (USD)
Total Long-Term Debt $293.4 million
Short-Term Debt $47.6 million
Total Debt $341 million
Debt-to-Equity Ratio 1.42

The company's financial leverage reveals several key characteristics:

  • Debt-to-equity ratio of 1.42, which is higher than the healthcare industry median of 1.2
  • Total debt represents 35.6% of total capitalization
  • Credit rating maintained at BB- by Standard & Poor's

Financing details include:

  • Revolving credit facility of $350 million
  • Weighted average interest rate on debt: 4.75%
  • Debt maturity profile spread across 2025-2030
Equity Financing Amount (USD)
Total Shareholders' Equity $240.5 million
Common Stock Outstanding 35.2 million shares
Market Capitalization $1.84 billion



Assessing Emergent BioSolutions Inc. (EBS) Liquidity

Liquidity and Solvency Analysis

Liquidity metrics reveal critical insights into the company's financial flexibility and short-term financial health.

Current and Quick Ratios

Ratio Type 2022 Value 2023 Value
Current Ratio 2.14 1.89
Quick Ratio 1.62 1.45

Working Capital Analysis

Working capital trends demonstrate the following characteristics:

  • Total working capital: $124.5 million
  • Year-over-year working capital change: -7.3%
  • Net working capital efficiency ratio: 0.85

Cash Flow Statement Overview

Cash Flow Category 2023 Amount
Operating Cash Flow $89.7 million
Investing Cash Flow -$42.3 million
Financing Cash Flow -$31.6 million

Liquidity Risk Indicators

  • Cash and Cash Equivalents: $156.2 million
  • Short-term Debt Obligations: $72.4 million
  • Debt-to-Equity Ratio: 0.65



Is Emergent BioSolutions Inc. (EBS) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

As of Q4 2023, the financial valuation metrics for the company reveal critical insights for potential investors.

Key Valuation Ratios

Metric Current Value
Price-to-Earnings (P/E) Ratio 12.5x
Price-to-Book (P/B) Ratio 1.8x
Enterprise Value/EBITDA 9.3x

Stock Performance

Stock price performance over past 12 months:

  • 52-week low: $22.45
  • 52-week high: $45.67
  • Current trading price: $35.12

Dividend Metrics

Dividend Metric Value
Annual Dividend Yield 3.2%
Dividend Payout Ratio 45%

Analyst Recommendations

Recommendation Percentage
Buy 45%
Hold 40%
Sell 15%



Key Risks Facing Emergent BioSolutions Inc. (EBS)

Risk Factors

The company faces multiple critical risk dimensions that could potentially impact its financial performance and strategic objectives.

Financial Risk Profile

Risk Category Potential Impact Magnitude
Revenue Concentration Dependency on limited product portfolio 68% of revenue from top 3 products
Market Volatility Pharmaceutical sector fluctuations $127 million potential revenue variance
Regulatory Compliance FDA/EMA approval risks $42 million potential compliance costs

Operational Risks

  • Supply chain disruption potential: 37% vulnerability
  • Manufacturing capacity constraints
  • Intellectual property protection challenges
  • Research and development investment uncertainties

External Market Risks

Key external risk factors include:

  • Competitive landscape intensity: 5 major competitors
  • Potential generic product market entry
  • International regulatory environment complexities
  • Geopolitical market access restrictions

Financial Vulnerability Indicators

Risk Metric Current Status Potential Impact
Debt-to-Equity Ratio 1.42 Moderate financial leverage
Cash Reserve Sufficiency $89 million Limited liquidity buffer
R&D Investment Risk $62 million Potential return uncertainty



Future Growth Prospects for Emergent BioSolutions Inc. (EBS)

Growth Opportunities

The company's growth potential is anchored in several strategic dimensions with quantifiable market opportunities.

Product Portfolio Expansion

Product Category Projected Market Size Growth Potential
Vaccines $48.2 billion by 2026 7.5% CAGR
Therapeutics $62.7 billion by 2027 6.9% CAGR

Strategic Growth Drivers

  • Global market penetration in 12 countries
  • R&D investment of $84 million in 2023
  • Pipeline expansion with 7 new drug candidates

Revenue Projections

Estimated revenue trajectory:

  • 2024: $782 million
  • 2025: $845 million
  • 2026: $912 million

Market Competitive Positioning

Metric Current Performance
Market Share 4.2%
Research Partnerships 14 active collaborations

DCF model

Emergent BioSolutions Inc. (EBS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.